請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59514完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 段維新(Wei-Hsing Tuan) | |
| dc.contributor.author | Man-Ping Chang | en |
| dc.contributor.author | 張曼蘋 | zh_TW |
| dc.date.accessioned | 2021-06-16T09:26:15Z | - |
| dc.date.available | 2019-07-20 | |
| dc.date.copyright | 2017-07-20 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-06-05 | |
| dc.identifier.citation | [1] W. R. Moore, S. E. Graves and G. I. Bain, “Synthetic bone graft substitutes,” ANZ J. Surg. 71, 354–36, (2001).
[2] P. R. Klokkevold, S. A. Jovanovic. “Advanced implant surgery and bone grafting techniques,” In Newman, MG; Takei, HM; Carranza, FA. Carranza's Clinical Periodontology (9th ed.). Philadelphia: W.B. Saunders, 2002, pp. 907–8. [3] W. S. Pietrzak, R. Ronk, “Calcium sulfate bone void filler: a review and a look ahead,” J Craniofac Surg.11, 327-333, (2000). [4] C. L. M. Bao, E. Y. Teo, M. S.K. Chong, Y. Liu, M. Choolani and J. K.Y. Chan, Advances in Bone Tissue Engineering, Regenerative Medicine and Tissue Engineering, 2013. [5] M. G Ascenzi and A. K Roe, “The osteon: the micromechanical unit of compact bone,” Front Biosci, 1551-1581, (2012). [6] D. W. Buck and G. A. Dumanian, “Bone Biology and Physiology: Part I. The Fundamentals,” Plast. Reconstr. Surg. 129, 1314-1320, (2012). [7] J. Aerssens, J. Dequeker and J. M. Mbuyimuamba, “Bone tissue composition: biochemical anatomy of bone,” Clin Rheumatol, 54-62, (1994). [8] S.M. Barinov, “Calcium phosphate-based ceramic and composite materials for medicine,” Russian Chemical Reviews 79 (1) 13- 29, (2010). [9] A+醫學百科「成骨細胞」 http://cht.a-hospital.com/w/%E6%88%90%E9%AA%A8%E7%BB%86%E8%83%9E [10] R. J. O’Keefe and J. Mao, “Bone tissue engineering and regeneration: from discovery to the clinic—an overview,” Tissue Eng Part B Rev, 17, 389-392, (2011). [11] M. Bohner, “Resorbable biomaterials as bone graft substitutes,” Mater Today, 13, 26-30, (2010). [12] S. Freiberg and X. X. Zhu, “Polymer microspheres for controlled drug release,” Int J Pharm. 282 (1-2), 1-18, (2004). [13] F. Witte, J. Fischer, J. Nellesen, H. A. Crostack, V. Kaese, A. Pisch, F. Beckmann and H. Windhagen, “In vitro and in vivo corrosion measurements of magnesium alloys,” Biomaterials, 27 (7), 1013-1018, (2006). [14] F. Tamimi, J. Torres, C. Kathan, R. Baca, C. Clemente, L. Blanco and E. L. Cabarcos, J Biomed Mater Res. 87A (4), 980-985, (2008). [15] S. Yamada, D. Heymann, J.-M. Bouler and G. Daculsi, “Osteoclastic resorption of calcium phosphate ceramics with different hydroxyapatite/β-tricalcium phosphate ratios,” Biomaterials, 18 (15), 1037-1041, (1997). [16] M. Vert, “Polymeric biomaterials: Strategies of the past vs. strategies of the future ,” Prog Polym Sci., (Oxford) 32 (8-9), 755-761, (2007). [17] D. W. Hutmacher, “Scaffolds in tissue engineering bone and cartilage,” Biomaterials, 21 (24), 2529-2543, (2000). [18] J. R. E. Fraser, T. C. Laurent, A. Engström-Laurent and U. G. B. Laurent, “Elimination of hyaluronic acid from the blood stream in the human,” Clin Exp Pharmacol P, 11 (1), 17-25, (1984). [19] J.-K. F. Suh, and H. W. T. Matthew., “Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review,” Biomaterials, 21 (24), 2589-2598, (2000). [20] P. Habibovic and K. de Groot, “Osteoinductive biomaterials—properties and relevance in bone repair,” J Tissue Eng Regen Med., 1 (1), 25-32, (2007). [21] B. Zberg, P. J. Uggowitzer and J. F. Löffler, “MgZnCa glasses without clinically observable hydrogen evolution for biodegradable implants,” Nat Mater., 8 (11), 887-89, (2009). [22] S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, 289 (5484), 1504-1508, (2000). [23] K. Ohura, M. Bohner, P. Hardouin, J. Lemaître, G. Pasquier and B. Flautre, “Resorption of, and bone formation from, new β-tricalcium phosphate-monocalcium phosphate cements: An in vivo study,” J Biomed Mater Res., 30 (2), 193-200, (1996). [24] P. Habibovic, U. Gbureck, C. J. Doillon, D. C. Bassett, C. A. van Blitterswijk and J. E. Barralet, “Osteoconduction and osteoinduction of low-temperature 3D printed bioceramic implants,” Biomaterials, 29 (7), 944-953, (2008). [25] M. Ikenaga, P. Hardouin, J. Lemaître, H. Andrianjatovo and B. Flautre, “Biomechanical characterization of a biodegradable calcium phosphate hydraulic cement: A comparison with porous biphasic calcium phosphate ceramics,” J Biomed Mater Res., 40 (1), 139-144, (1998). [26] N. Passuti, Daculsi, G. Daculsi, Rogez, J. M. Rogez, S. Martin and J. V. Bainvel, “Macroporous calcium phosphate ceramic performance in human spine fusion,” Clin Orthop Relat R. 248, 169-176, (1989). [27] D. Eglin and M. Alini, “Degradable polymeric materials for osteosynthesis: tutorial,” Eur Cells Mater., 16, 80-91, (2008). [28] O. Suzuki, H. Imaizumi, S. Kamakura and T. Katagiri, “Bone regeneration by synthetic octacalcium phosphate and its role in biological mineralization,” Curr Med Chem., 15(3), 305-313, (2008). [29] R. Z. LeGeros, “Biodegradation and bioresorption of calcium phosphate ceramics,” Clinical Materials, 14, 65-88, (1993). [30] M. V. Thomas and D. A. Puleo, “Calcium sulfate: properties and clinical applications,” J Biomed Mater Res B Appl Biomater, 88B, 597–610, (2009). [31] F. Wirsching, “Calcium Sulfate,” Ullmann's encyclopedia of industrial chemistry, 6, 519-550, (2012). [32] R. M. Gruver, “Differential Thermal‐Analysis Studies of Ceramic Materials: III, Characteristic Heat Effects of Some Sulfates,” J. Am. Ceram. Soc., 34, 353 – 357, (1951). [33] N.B. Singh, B. Middendorf, “Calcium sulphate hemihydrate hydration leading to gypsum crystallization,” Prog. Cryst. Growth Charact. Mater., 53, 57-77, (2007). [34] M. J. Ridge, “Mechanism of setting of gypsum plaster,” Rev. Pure App. Chem., 10, 243-276, (1960). [35] M. J. Ridge and J. Beretka, “Calcium sulphate hemihydrate and its hydration,” Rev. Pure Appl. Chem., 19, 17, (1969). [36] F. Ullmann, W. Gerhartz, Y. S. Yamamoto, F. T. Campbell, R. Pfefferkorn and J. F. Rounsaville, “Ullmann's encyclopedia of industrial chemistry,” Weinheim, Germany: Vch, 477-479, (1985). [37] A. N. Christense, T. R. Jensen and A. Nonat, “A new calcium sulfate hemi-hydrate,” Dalton Trans., 39, 2044–2048, (2010). [38] H. U. Hummel, B. Abdussaljamow, H. B. Fischer and J. Stark, “Untersuchungen zur hygro-mechanischen Stabilität von kristallinem Calciumsulfat-Halbhydrat, ” IBAUSIL. Tagung, pp. 1-0067, (2000). [39] S. Follner, A. Wolter, A. Preusser, S. Indris, C. Silber and H. Follner, “The setting behaviour of α- and β-CaSO4• 0.5 H2O as a function of crystal structure and morphology,” Cryst. Res. Technol., 37, 1075-1087, (2002). [40] R. J. Hand, ” Calcium sulphate hydrates: a review,” Br. Ceram. Trans., 96, 116-120, (1997). [41] V. Satava, “Sprechsaal Keramik,” Glas, Email, 103, 792, (1970). [42] H.J. Kuzel and M. Hauner, “Chemische und kristallographische Eigenschaften von Calciumsulfat-Halbhydrat und Anhydrit III,” ZKG international, 40, 628-632, (1987). [43] C. Bezou, A. Nonat, J.-C. Mutin, A. N. Christensen and M. S. Lehmann, “Investigation of the crystal structure of γ-CaSO4, CaSO4• 0.5 H2O, and CaSO4• 0.6 H2O by powder diffraction methods,” J. Solid State Chem., 117, 165-176, (1995). [44] N. N. Bushuev and V. M. Borisov, “X-ray diffraction investigation of CaSO4• 0.67 H2O,” Russ. J. Inorg.Chem., 37, 341-343, (1982). [45] P. Ballirano, A. Maras, S. Meloni and R. Caminiti, “The monoclinic I2 structure of bassanite, calcium sulphate hemihydrate (CaSO4• 0.5 H2O),” Eur. J. Mineral., 13, 985-993, (2001). [46] M. Oetzel, F. D. Scherberich and G. Heger, “Heating device for high temperature X-ray powder diffraction studies under controlled water vapour pressure (0–1000 mbar) and gas temperature (20–200°C), ” Powder Diffr., 15, 30-37, (2000). [47] M. Oetzel, G. Heger and T. Koslowski, “Influence of ambient moisture and temperature on the phase transitions in the CaSO4-H2O system-a contribution to the production of single-phase binders from FGD gypsum,” ZKG International, 53, 354-361, (2000) [48] H. Sattler and H. P. Bruckner, “Changes in volume and density during the hydration of gypsum binders as a function of the quantity of water available,” ZKG International, 54, 522-529, (2001). [49] M. Goto, B. Molony, M.J. Ridge and G.W. West, “The forms of calcium sulphate hemihydrate,” Aust. J. Chem., 19, 313-316, (1966). [50] H. Dreesman, “Ueber Knochenplombierung,” Beitr. Klin Chir., 9, 804-810 (1892). [51] R. Lillo R and L. F. Peltier, “The substitution of plaster of Paris rods for portions of the diaphysis of the radius in dogs,” Surg Forum, 6, 556–558, (1956). [52] L. F. Peltier, E. Y. Bickel, R. Lillo, M. S. Thein, “The use of plaster of paris to fill defects in bone,” Ann Surg, 146, 61–69, (1957). [53] S. J. Bier and M. C. Sinensky, “The versatility of calcium sulfate: Resolving periodontal challenges,” Compend Contin Educ Dent, 20, 655–661; Quiz 662, (1999). [54] S. P. Nielsen, “The biological role of strontium,” Bone, 35, 583– 588 (2004). [55] P. J. Meunier, R. S. Lorenc and I. G. Smith, “Strontium ranelate: new efficient antiosteoporotic agent for treatment of vertebral osteoporosis in postmenopausal women,” Osteoporos Int, 13(Suppl 3):S34, (2002). [56] P. J. Meunier, C. Roux, E. Seeman, S. Ortolani and J. E. Badurski, “The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis,” N Engl J Med, 350, 459–468, (2004). [57] J. Y. Reginster, A. Sawicki, J. P. Devogelaer, J. M. Padrino, “Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis,” Osteoporos Int, 13, S14, (2002). [58] E. Shorr and A. C. Carter, “The usefulness of strontium as an adjuvant to calcium in the mineralization of the skeleton in man.” Hosp Joint Dis, 13, 59 – 66, (1952). [59] P. J. Marie, “Effects of strontium on bone tissue and bone cell,” In: Ne`ve, et al, editors. Therapeutic uses of trace elements. New York: Plenum; 1996, pp. 277– 282. [60] M. D. Grynpas, E. Hamilton, R. Cheung, “Strontium increases vertebral bone volume in rats at a low dose that does not induce mineralization defect,” Bone, 18, 253–359, (1996). [61] J. L. Omdahl and H. F. DeLuca, “Regulation of vitamin D metabolism and function,” Physiol Rev, 55, 327– 372, (1973). [62] P. Delannoy, D. Bazot D, P. J. Marie. “Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice,” Metabolism, 51, 906– 911, (2002). [63] P. J. Marie, P. Ammann, G. Boivin and C. Rey, “Mechanisms of action and therapeutic potential of strontium in bone,” Calcif Tissue Int, 69, 121–129, (2001). [64] G. Karsenty, “Bone - more than a standalone organ: a system sharing multiple connections with other tissues,” Medicographia, 32, No. 4, (2010). [65] ISO 10993-14, Biological evaluation of medical devices - Part 14: Identification and quantification of degradation products from ceramics. [66] ISO 10993-5, Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity. [67] ISO 10993-12, Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials. [68] R. J. Parrington, “Fractography of metals and plastics,” Practical Failure Analysis, 2, 16-19, (2002). [69] H. K. D. H. Bhadeshia, “Solid Solutions: The Hume-Rothery Rules,” Retrieved, (2007). [70] W. Smith and J. Hashemi, “Foundations of Materials Science and Engineering,” 4th ed., pp.139-140, (2006). [71] M. Miyake, I. Minato, H. Morikawa and S. I. Iwai, “Crystal structures and sulphate force constants of barite, celestite, and anglesite,” American Mineralogist, 63, 506-510, (1978). [72] International Tables for X-Ray Crystallography, Birmingham, England (1968). [73] R. L. Coble, “Sintering Crystalline Solids. I. Intermediate and Final State Diffusion Models,” Journal of Applied Physics, 32, 787-792, (1961). [74] E. W. Skinner and R. W. Phillips, “The science of dental materials,” 6th ed. Philadelphia: W. B. Saunders, 51-69, (1967). [75] K. J. Anusavice, C. Shen and H. R. Rawls, Gypsum Products, Phillips' Science of Dental Materials, Chapter 9, 182-193, (2013). [76] S. J. L. Kang, Sintering: densification, grain growth and microstructure. Butterworth-Heinemann, 2004. [77] J. Svoboda and H. Riedel, “Pore-boundary interactions and evolution equations for the porosity and the grain size during sintering,” Acta metall, mater., 40, 2829-2840, (1992). [78] H.R. Lashgari, M. Emamya, A. Razaghianb, A.A. Najimia, “The effect of strontium on the microstructure, porosity and tensile properties of A356–10%B4C cast composite,” Mat Sci Eng A-Struct, 517, 170–179, (2009). [79] H. Liao, Y. Sun and G. Sun, “Correlation between mechanical properties and amount of dendritic α-Al phase in as-cast near-eutectic Al–11.6% Si alloys modified with strontium,” Mat Sci Eng A-Struct, 335, 62–66, (2002). [80] T. Kokubo, Bioceramics and their Clinical Applications, Elsevier, 2008. [81] F. Linde, I. Hvid and B. Pongsoipeetch, “Energy absorptive properties of human trabecular bone specimens during axial compression,” J. Orthop. Res., 7, 432-439, (1989). [82] F. P. Knudsen, “Dependence of mechanical strength of brittle polycrystalline specimens on porosity and grain size,” J. Am. Ceram. Soc., 42, 376-378, (1959). [83] M. L. Syu, “Preparation of β-tricalcium phosphate and its composite by solid-state reaction method,” M.S. thesis, National Taiwan University, Taiwan, 2017. [84] S. Andreana, R. Cornelini, L. E. Edsberg, J. R. Natiella, “Maxillary sinus elevation for implant placement using calcium sulfate with and without DFDBA: Six cases,” Implant Dent, 13, 270–277, (2004). [85] B. Shi, Y. Zhou, Y. N. Wang, X. R. Cheng, “Alveolar ridge preservation prior to implant placement with surgical-grade calcium sulfate and platelet-rich plasma: A pilot study in a canine model,” Int J Oral Maxillofac Implants, 22, 656–665, (2007). [86] A.G. Dias, I.R. Gibson, J.D. Santos and M.A. Lopes, “Physicochemical degradation studies of calcium phosphate glass ceramic in the CaO–P2O5–MgO–TiO2 system,” Acta Biomaterialia, 3, 263–269, (2007). [87] R. Baron, L. Neff, D. Louvard and P. J. Courtoy, “Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border,” The Journal of cell biology, 101, 2210-2222, (1985). [88] S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, 289, 1504-1508, (2000). [89] N. A. Athanasou, “Current Concepts Review Cellular Biology of Bone-Resorbing Cells,” J Bone Joint Surg Am, 78, 1096-1112, (1996). [90] T. Winkler, E. Hoenig, R. Gildenhaar, G. Berger, D. Fritsch R. Janssen, M.M. Morlock and A.F. Schilling, “Volumetric analysis of osteoclastic bioresorption of calcium phosphate ceramics with different solubilities,” Acta Biomaterialia, 6, 4127–4135, (2010). [91] A. F. Schilling, W. Linhart, S. Filke, M. Gebauer, T. Schinke, J. M. Rueger and M. Amling, “Resorbability of bone substitute biomaterials by human osteoclasts,” Biomaterials, 25, 3963–3972, (2004). [92] M. C. Siebers, K. Matsuzaka, X. F. Walboomers, S. C. G. Leeuwenburgh, J. G. C. Wolke and J. A. Jansen, “Osteoclastic resorption of calcium phosphate coatings applied with electrostatic spray deposition (ESD), in vitro,” Published online 15 July 2005 in Wiley InterScience (www.interscience.wiley.com). [93] F. Monchau, A. Lefe`vre, M. Descamps, A. Belquin-myrdycz, P. Laffargue and H.F. Hildebrand, “In vitro studies of human and rat osteoclast activity on hydroxyapatite, b-tricalcium phosphate, calcium carbonate,” Biomol Eng., 19, 143-152, (2002). [94] H. Benghuzzi, A. Puckett, M. Tucci and B. Roberts, “Bioceramics surface modification by means of osteoclasts in culture,” Biomed Sci Instrum, 35, 321–326, (1999). [95] C. M. Miiller-Mai, S. I. Stupp, C. Voigt and U. Gross, “Nanoapatite and organoapatite implants in bone: Histology and ultrastructure of the interface,” J Biomed Mater Res, 29, 9-18, (1995). [96] S. Leeuwenburgh, P. Layrolle, F. Barre`re, J. de Bruijn, J. Schoonman, C.A. van Blitterswijk and K. de Groot, “Osteoclastic resorption of biomimetic calcium phosphate coatings in vitro,” J Biomed Mater Res, 56, 208-215, (2001). [97] S. J. Jones, A. Boyde, and N. N. All, “The resorption of biological and non-biological substrates by cultured avian and mammalian osteoclasts,” Anat Embryol, 170, 247-256, (1984). [98] M. Sidqui, P. Collin, C. Vitte and N. Forest, “Osteoblast adherence and resorption activity of isolated osteoclasts on calcium sulphate hemihydrate,” Biomoterids, 16, 1327-1332, (1995). [99] D. Yanga, Z. Yanga, X. Lia, L. Z. Dib and H. Zhao, “A study of hydroxyapatite/calcium sulphate bioceramics,” Ceram Int, 31, 1021–1023, (2005). [100] Z. Huan, J. Chang, “Self-setting properties and in vitro bioactivity of calcium sulfate hemihydrate–tricalcium silicate composite bone cements,” Acta Biomaterialia, 3, 952–960, (2007). [101] K. N. Lewis, M. V. Thomas and D. A. Puleo, “Mechanical and degradation behavior of polymer-calcium sulfate composites,” J Mater Sci: Mater Med, 17, 531–537, (2006). [102] C. Gao, J. Gao, X. You, S. Huo, X. Li, Y. Zhang and W. Zhang, “Fabrication of calcium sulfate/PLLA composite for bone Repair,” J Biomed Mater Res A, 73, 244-253, (2005). [103] W. M. Haynes, CRC Handbook of Chemical and Physics, 91st edition(Internet Version) CRC Press/Taylor and Francis, Boca Raton, FL, (2001). [104] R. M. Urban, T. M. Turner, D. J. Hall, N. Inoue and S. Gitelis, “Increasing bone formation using calcium sulfate-calcium phosphate composite graft,” Clin. Orthopaed. Rel. Res., 459, 110-119, (2007). [105] S. G. Dahl, P. Allain, P. J. Marie, Y. Mauras, G. Boivin, P. Ammann, Y. Tsouderos, P. D. Delmas and C. Christiansen, “Incorporation and Distribution of Strontium in Bone,” Bone, 28, 446–453, (2001). [106] E. F. Ferraro, R. Carr, and K. Zimmerman, “A comparison of the effects of strontium chloride and calcium chloride on alveolar bone,” Calcif Tissue Int, 35, 258 –260, (1983). [107] M. D. Grynpas and P. J. Marie, “Effects of low doses of strontium on bone quality and quantity in rats,” Bone, 11, 313–319, (1990). [108] P. J. Marie, G. Chabot, F. H. Glorieux, and S. C. Skoryna, “Histomorphometry of bone changes in human subjects following low dosage of stable strontium,” In: Hemphill, D. D., Ed. Proceedings of the 19th Annual Conference on Trace Substances in Environmental Health. Columbia, MO: University of Missouri; 193–208, (1985). [109] P. J. Marie, M. H. Garba, M. Hott and L. Miravet, “Effect of low doses of stable strontium on bone metabolism in rats,” Miner Electrolyte Metab, 11, 5–13, (1985). [110] P. J. Marie and M. Hott, “Short-term effects of fluoride and strontium on bone formation and resorption in the mouse,” Metabolism, 35, 547–551, (1986). [111] A. Matsumoto, “Effect of strontium chloride on bone resorption induced by prostaglandin E2 in cultured bone,” Arch Toxicol, 62, 240 –24, (1988). [112] Y. Su, J. P. D. Bonnet and Y. R. B. Tsouderos, “The strontium salt S12911 inhibits the expression of carbonic anhydrase and the vitronectin receptor in chicken bone marrow cultures and bone resorption in mouse calvaria and isolated rat osteoclasts,” J Bone Miner Res, 7, S306, (1992). [113] K. Anselme, “Osteoblast adhesion on biomaterials,” Biomaterials, 21, 667-681, (2000). [114] B. D. Boyan, T. W. Hummert, D. D. Dean, Z. Schwartz, “Role of material surfaces in regulating bone and cartilage cell response,” Biomaterials, 17, 137-146, (1996). [115] J. C. Keller, C. M. Stanford, J. P. Wightman, R. A. Draughn and R. Zaharias, “Characterizations of titanium implant surfaces. III,” J Biomed Mater Res, 28,939-946, (1994). [116] U. Meyer, D.H. Szulczewski, K. Moller, H. Heide and D.B. Jones, “Attachment kinetics and differentiation of osteoblasts on different biomaterials,” Cells Mater, 3, 129–140, (1993). [117] D. De Santis, C. Guerriero, P. F. Nocini, A. Ungersbock, G. Richards, P. Gotte and U. Armato, “Adult human bone cells from jaw bones cultured on plasma-sprayed or polished surfaces of titanium or hydroxyapatite discs,” J Mater Sci-Mater Med, 7, 21-28, (1996). [118] A. Naji and M. F. Harmand. “Study of the effect of the surface state on the cytocompatibility of a Co‐Cr alloy using human osteoblasts and fibroblasts,” J Biomed Mater Res, 24, 861-71, (1990). [119] C. R. Howlett, M. D. M. Evans, W. R. Walsh, G. Johnson, J. G. Steele, “Mechanism of initial attachment of cells derived from human bone to commonly used prosthetic materials during cell culture,” Biomaterials, 15, 213-222, (1994). [120] D. A. Puleo, R. Bizios, “Formation of focal contacts by osteoblasts cultured on orthopaedic biomaterials,” J Biomed Mater Res, 26, 291-301, (1992). [121] A. Hunter, C. W. Archer, P. S. Walker and G. W. Blunn, “Attachment and proliferation of osteoblasts and fibroblasts on biomaterials for orthopaedic use,” Biomaterials, 16, 287-295, (1995). [122] K. Kieswetter, Z. Schwartz, T. W. Hummert, D. L. Cochran, J. Simpson, D. D. Dean, and B. D. Boyan, “Surface roughness modulates the local production of growth factors and cytokines by osteoblast-like MG-63 cells,” J Biomed Mater Res, 32, 55-63, (1996). [123] K. Anselme, M. Bigerelle, B. Noel, E. Dufresne, D. Judas, A. Iost and P. Hardouin, “Qualitative and quantitative study of human osteoblast adhesion on materials with various surface roughness,” J Biomed Mater Res, 49, 155–166, (2000). [124] K. D. Chesmel, C. C. Clark, C. T. Brighton and J. Black, “Cellular responses to chemical and morphologic aspects of biomaterial surfaces. II. The biosynthetic and migratory response of bone cell populations,” J Biomed Mater Res, 29, 1101-1110, (1995). [125] J. Park, S. Bauer, K. V. D. Mark and P. Schmuki, “Nanosize and Vitality: TiO2 nanotube diameter directs cell fate,” Nano Lett., 7, 1686-1691, (2007). [126] J. Takagi B. M. Petre, T. Walz, T. A. Springer, “Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling,” Cell, 110, 599-511, (2002). [127] M. Rajagopalan, M.A. Tschopp and K.N. Solanki, “Grain boundary segregation of interstitial and substitutional impurity atoms in alpha-iron,” JOM (Journal of Materials) 66. 129-138, (2014). [128] P. Ducheyne, K. Healy, D. E. Hutmacher, D. W. Grainger and C. J. Kirkpatrick, Comprehensive Biomaterials, Newnes, pp. 218-219, (2015). [129] J. L. Ricci and M. J. Weiner. In Bioceramics and Their Clinical Applications; T. Kokubo Ed; CRC/Woodhead: Boca Raton, FL, pp.302-325, (2008). | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59514 | - |
| dc.description.abstract | 硫酸鈣 (CaSO4，CS) 作為骨替代材已行之有年，其具備生物相容性、骨融合和骨傳導性，因此硫酸鈣移植物不會引起發炎反應，且可幫助新骨細胞生長。另外，硫酸鈣具備生物可吸收性，可在移植後在體內被完全降解，因此不須經過二次手術移除。
鍶離子具備抗骨質疏鬆的特性，其機制為可促進骨質生成，同時抑制骨質吸收。鍶離子可刺激前成骨細胞複製分化為成骨細胞，且促進膠原蛋白分泌，以此達到促進骨質生成的效果；同時，增加蝕骨細胞抑制因子，以抑制蝕骨細胞的生成及活性，進而抑制骨質流失。 在本研究中，以燒結法製備摻雜鍶之無水硫酸鈣試樣。將10 wt%之硫酸鍶與半水硫酸鈣粉末混合，燒結至1200°C後持溫一小時，此熱處理流程可使鍶離子置換硫酸鈣內的鈣離子，形成一結構緻密的摻雜鍶之無水硫酸鈣試樣。此試樣經過降解測試結果顯示，試樣可在降解的同時釋放鍶離子；另外，在細胞毒性測試上表現出良好的生物相容性，且細胞可在試樣上貼附生長。整體而言，此鍶鈣材料具有良好的潛力作為一可降解並同時抗骨質疏鬆的骨替代材。 | zh_TW |
| dc.description.abstract | Calcium sulfate (CaSO4, CS) has been used as bone graft substitute for more than 100 years. It exhibits well-tolerated and biocompatible properties, osseointegration and osteoconduction. Therefore, calcium sulfate implant induces minimal inflammatory responses in vivo, and can support bone cells to growth over it surface. In addition, calcium sulfate can be resorbed in vivo completely, it is an important property for a bone graft substitute that can avoid additional operation for implant removal.
Strontium ion is known for its antiosteoporotic effect. The mechanism is a dual mode that strontium can enhance bone formation and inhibit bone resorption simultaneously. For bone formation, strontium can stimulate the replication of preosteoblast and induce the secretion of collagen, leading to increase bone matrix. In parallel, strontium can inhibit the differentiation and activity of osteoclasts by upregulation the ratio of osteoprotegerin (OPG) / receptor activator of nuclear factor kappa-B ligand (RANKL) in osteoclast, and leading to the decrease of bone resorption In the present study, sintering technique is used to prepare calcium sulfate anhydrate specimens incorporating strontium ion. An amount of 10wt% strontium sulfate powder is added into calcium sulfate hemihydrate powder, then sintered at 1200°C for 1 hour to form the strontium-substituted calcium sulfate. The degradation results show that strontium ion release during the specimen degradation simultaneously. In addition, both indirect and direct cytotoxicity results demonstrate the biocompatibility. In conclusion, the strontium-substituted calcium sulfate specimen is a potential material that not only bioresorbable but antiosteoporotic as a novel bone graft substitute. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T09:26:15Z (GMT). No. of bitstreams: 1 ntu-106-D01527003-1.pdf: 7908548 bytes, checksum: 2317f29a3002dba7b83331cf00bd7fe2 (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 口試委員會審定書 #
中文摘要 i ABSTRACT ii CONTENTS iii LIST OF FIGURES vi LIST OF TABLES xi Chapter 1 Introduction 1 Chapter 2 Literature review 3 2.1 Basics of bone and bone tissue 3 2.2 Resorbable materials as bone graft substitutes 6 2.3 Use of calcium sulfate as bioceramics 8 2.3.1 Chemical and physical properties of calcium sulfate…………..……...8 2.3.2 Biological properties and clinical applications of calcium sulfate…...13 2.4 Biological properties and clinical applications of strontium 14 Chapter 3 Experimental procedures 16 3.1 Calcium sulfate 16 3.1.1 Starting material……………………………………………………..16 3.1.2 Processing…………………………………………………………...16 3.1.3 Characterization……………………………………………………..18 3.1.3.1 Material properties…………………………….……………..18 3.1.3.2 Biological properties…………………………………………19 3.2 Strontium compounds 24 3.2.1 Starting materials 24 3.2.2 Processing 24 3.2.3 Characterization……………………………………………………..24 3.2.3.1 Material properties………………………………………….24 3.2.3.2 Biological properties………………………………………..24 Chapter 4 Results 25 4.1 Calcium sulfate 25 4.1.1 Material properties…………………………………………………..25 4.1.1.1 Phase identification…………………………………………..25 4.1.1.2 Density and weight loss……………………………………...26 4.1.1.3 Microstructure observation…………………………………..28 4.1.2 Biological properties……………………………………………...…29 4.1.2.1 Degradation test……………………………………………...29 4.1.2.2 Cytotoxicity-test on extracts…………………………………34 4.1.2.3 Cytotoxicity-test by direct contact…………………………...35 4.2 Strontium compounds 38 4.2.1 Material properties…………………………………………………..38 4.2.1.1 Phase identification…………………………………………..38 4.2.1.2 Density and weight loss……………………………………...40 4.2.1.3 Microstructure observation…………………………………..44 4.2.1.4 Mechanical property…………………………………………46 4.2.2 Biological properties………………………………….……………..47 4.2.2.1 Degradation test……………………………………………...47 4.2.2.2 Cytotoxicity-test on extracts…………………………………53 4.2.2.3 Cytotoxicity-test by direct contact………………………...…55 4.2.2.4 Animal test – rat calvarial model…………………………….59 Chapter 5 Discussion 62 5.1 Material properties 62 5.1.1 Phase identification………………………………………………….62 5.1.2 Density and weight loss……………………………………………..67 5.1.3 Microstructure observation………………………………………….70 5.1.4 Mechanical property………………………………………………...71 5.2 Biological properties 73 5.2.1 Degradation test……………………………………………………..73 5.2.2 Cytotoxicity-test on extracts………………………………………...81 5.2.3 Cytotoxicity-test by direct contact……………………………….….82 5.2.4 Animal test – rat calvarial model……………………………………85 Chapter 6 Conclusions……………………………………………………………..87 Appendix Precipitates of degradation test…………..……………………..…......88 REFERENCE 94 | |
| dc.language.iso | en | |
| dc.title | 摻雜鍶離子之硫酸鈣作為骨替代材之研究 | zh_TW |
| dc.title | Strontium-Doped Calcium Sulfate Anhydrate as Bone Graft Substitute | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 105-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 王錫福(Sea-Fue Wang),林?輝(Feng-Huei Lin),劉典謨(Dean-Mo Liu),賴伯亮(Po-Liang Lai) | |
| dc.subject.keyword | 硫酸鈣,鍶,生物可吸收,燒結, | zh_TW |
| dc.subject.keyword | calcium sulfate,strontium,bioresorbable,sintering, | en |
| dc.relation.page | 107 | |
| dc.identifier.doi | 10.6342/NTU201700851 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-06-05 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 材料科學與工程學研究所 | zh_TW |
| 顯示於系所單位： | 材料科學與工程學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 目前未授權公開取用 | 7.72 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。